EINAT BRILL ALMON, PH.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Protalix BioTherapeutics, Inc.

Filing Date Source Excerpt
2017-08-25 The following table sets forth information, as of August 10, 2017, regarding beneficial ownership of our common stock: Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage of Class (%) Board of Directors and Executive Officers Einat Brill Almon, Ph.D.
2017-09-01 Board of Directors and Executive Officers Einat Brill Almon, Ph.D. Consists of 185,000 outstanding shares of our common stock and 597,522 shares of our common stock issuable upon exercise of outstanding options.
2018-10-17 Einat Brill Almon, Ph.D.(4)
2019-10-15 Security Ownership of Certain Beneficial Owners and Management table
2021-09-30 Einat Brill Almon, Ph.D. Consists of 18,500 outstanding shares of our common stock and 139,060 shares of our common stock issuable upon exercise of outstanding options

Data sourced from SEC filings. Last updated: 2026-02-08